FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 (X) QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended April 30, 1999 AND ( )TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-15266 BIO-REFERENCE LABORATORIES, INC. - ------------------------------------------------------------------------------ (Exact name of registrant as specified in its charter) NEW JERSEY 22-2405059 (State or other jurisdiction of (IRS Employer Identification No.) incorporation or organization) 481 Edward H. Ross Drive, Elmwood Park, NJ 07407 (Address of principal executive offices) (Zip Code) (Registrant's telephone number, including area code) (201) 791-2600 ---------------- - ------------------------------------------------------------------------ (Former name, former address and former fiscal year, if changed since last report) Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS Check whether the registrant filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities and Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court. Yes No APPLICABLE ONLY TO CORPORATE ISSUERS State the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 7,222,910 ($.01 par value) at June 8, 1999. BIO-REFERENCE, LABORATORIES, INC. FORM 10-Q APRIL 30, 1999 I N D E X Page PART I. FINANCIAL INFORMATION Item 1. Financial Statements Balance Sheet as of April 30, 1999 (unaudited) and October 31, 1998 1 Statements of Operations for the three months and six months ended April 30, 1999 and April 30, 1998 (unaudited) 3 Statements of Cash Flows for the six months ended April 30, 1999 and April 30, 1998 (unaudited) 4 Notes to financial statements 6 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 7 PART II. OTHER INFORMATION 10 Item 6. Exhibits and Reports on Form 8-K 10 Signatures 11 BIO-REFERENCE LABORATORIES, INC. BALANCE SHEETS ASSETS April 30, October 31, 1999 1998 (Unaudited) CURRENT ASSETS: Cash $ 2,329,975 $ 2,784,147 Accounts Receivable (Net) 19,013,156 20,749,696 Inventory 612,975 587,101 Other Current Assets 1,134,886 1,444,867 Certificates of Deposit- Restricted 3,646,250 3,646,250 --------- --------- TOTAL CURRENT ASSETS $26,737,242 $29,212,061 -------------------- ---------- ---------- PROPERTY, PLANT AND EQUIPMENT $ 4,517,808 $ 4,243,464 ----------------------------- LESS: Accumulated Depreciation 2,549,737 2,022,928 ---- --------- --------- TOTAL PROPERTY, PLANT AND EQUIPMENT - NET $ 1,968,071 $ 2,220,536 ------------------------- --------- --------- OTHER ASSETS: Certificate of Deposit - Restricted $ 33,750 $ 33,750 Due from Related Party 170,918 187,118 Deposits 241,148 303,354 Goodwill (Net of Accumulated Amortization of $1,425,615 and $1,248,029 respectively) 5,569,015 5,746,601 Deferred Charges (Net of Accumulated Amortization of $2,100,202 and $2,173,034 respectively) 1,356,381 2,507,149 Other Assets 595,892 567,769 ------- ------- TOTAL OTHER ASSETS $ 7,967,104 $ 9,345,741 ------------------ --------- --------- TOTAL ASSETS $36,672,417 $40,778,338 ------------ ========== ========== The Accompanying Notes are an Integral Part of These Financial Statements. 1 BIO-REFERENCE LABORATORIES, INC. BALANCE SHEETS LIABILITIES AND SHAREHOLDERS' EQUITY April 30, October 31, 1999 1998 (Unaudited) CURRENT LIABILITIES: Accounts Payable $ 4,864,182 $ 4,379,961 Salaries and Commissions Payable 1,211,563 1,367,785 Accrued Expenses 681,871 625,814 Current Portion of Long-Term Debt 2,000,153 2,071,058 Current Portion of Leases Payable 217,177 229,232 Notes Payable 12,000,000 12,000,000 Taxes Payable 387,272 173,962 ------- ------- TOTAL CURRENT LIABILITIES $21,362,218 $20,847,812 ------------------------- ---------- ---------- LONG-TERM LIABILITIES: Long-Term Portion of Long-Term Debt [Net of Discount] $ 2,280,920 $ 3,306,617 Long-Term Portion of Leases Payable 395,597 400,975 ------- ------- TOTAL LONG-TERM LIABILITIES $ 2,676,517 $ 3,707,592 --------------------------- --------- --------- SHAREHOLDERS' EQUITY: Preferred Stock $.10 Par Value; Authorized 1,062,589 shares, None Issued $ -- $ -- Series A-Senior Preferred Stock, $.10 Par Value; Authorized 604,078 shares, Issued and Outstanding 604,078 shares 60,408 60,408 Series A-Junior Participating Preferred Stock, par value $.10 per share, authorized 3,000 shares, none issued -- -- Common Stock, $.01 Par Value; Authorized 18,333,333 shares, Issued and Outstanding 7,222,910 shares in April 30, 1999 and 7,212,910 shares in October 31, 1998 72,229 72,129 Additional Paid-In Capital 23,007,915 22,998,015 Accumulated [Deficit] (10,269,244) (6,634,985) ---------- --------- Totals $12,871,308 $16,495,567 Deferred Compensation (237,626) (272,633) ------- ------- TOTAL SHAREHOLDERS' EQUITY $12,633,682 $16,222,934 -------------------------- ---------- ---------- TOTAL LIABILITIES AND --------------------- SHAREHOLDERS' EQUITY $36,672,417 $40,778,338 -------------------- ========== ========== The Accompanying Notes are an Integral Part of These Financial Statements. 2 BIO-REFERENCE LABORATORIES, INC. STATEMENTS OF OPERATIONS [UNAUDITED] Three months ended Six months ended April 30, April 30, 1 9 9 9 1 9 9 8 1 9 9 9 1 9 9 8 ------- ------- ------- ------- NET REVENUES: $13,419,503 $10,808,505 $26,059,986 $19,744,928 - ------------ ---------- ---------- ---------- ---------- COST OF SERVICES: Depreciation $ 217,879 $ 141,243 $ 437,325 $ 244,488 Employee Related Expenses 3,750,846 2,584,001 7,085,224 4,587,239 Reagents and Lab Supplies 1,704,875 1,230,795 3,320,162 2,292,144 Other Cost of Services 2,272,428 1,573,859 4,309,788 2,905,137 --------- --------- --------- --------- TOTAL COST OF SERVICES $ 7,946,027 $5,529,898 $15,152,499 $10,029,008 ---------------------- --------- --------- ---------- ---------- GROSS PROFIT ON REVENUES $ 5,473,476 $5,278,607 $10,907,487 $ 9,715,920 - ------------------------ General and Administrative Expenses: Depreciation and Amortization $ 247,368 $ 206,742 $ 493,468 $ 361,309 Other General and Admin. Expenses 3,855,399 3,271,863 7,545,003 6,137,998 Bad Debt Expense 1,702,139 1,497,952 2,984,230 2,739,162 Expenses of Abandoned Asset 2,924,371 -- 2,924,371 -- --------- ---------- --------- ---------- TOTAL GENERAL AND ADMIN. EXPENSES $ 8,729,277 $4,976,557 $13,947,072 $9,238,469 ---------------- --------- --------- ---------- --------- OPERATING INCOME $(3,255,801) $ 302,050 $(3,039,585) $ 477,451 - ---------------- OTHER (INCOME) EXPENSES: Interest Expense $ 375,903 $ 258,280 $ 778,997 $ 463,597 Interest Income (105,187) (111,228) (184,325) 189,853 --------- --------- --------- --------- TOTAL OTHER EXPENSES - NET $ 270,716 $ 147,052 $ 594,672 $ 273,744 --------------- ------- ------- ------- ------- INCOME (LOSS) BEFORE TAX $(3,526,517) $ 154,998 $(3,634,257) $ 203,707 ---------- Provision for Income Taxes -- 31,000 -- 41,717 ------ ----------- ------- ----------- NET INCOME (LOSS) $(3,526,517) $ 123,998 $(3,634,257) $ 161,990 - ----------------- =========== ======= =========== ======= NET INCOME (LOSS) PER SHARE: $ (.49) $ .02 $ (.50) $ .02 --------- == == == === NUMBER OF SHARES: 7,216,243 6,943,448 7,214,576 6,943,448 - ----------------- ========= ========= ========= ========= NET INCOME (LOSS) PER SHARE - ASSUMING DILUTION: (.44) .02 (.46) .02 ----------------- == == == == NUMBER OF SHARES: 7,970,337 7,977,004 7,968,670 7,977,004 - ---------------- ========= ========= ========= ========= The Accompanying Notes are an Integral Part of These Financial Statements. 3 BIO-REFERENCE LABORATORIES, INC. STATEMENTS OF CASH FLOWS [UNAUDITED] Six months ended April 30, 1 9 9 9 1 9 9 8 ------- ------- OPERATING ACTIVITIES: Net Income $(3,634,257) $ 161,990 Adjustments to Reconcile Net Income to Cash Provided by Operating Activities: Deferred Compensation 35,007 37,386 Compensation Expense 10,000 -- Depreciation and Amortization 930,793 605,797 Amortization of Deferred Assets 46,002 -- Expenses of Abandoned Asset 2,924,371 -- Provision for Bad Debts 2,984,230 2,739,162 Change in Assets and Liabilities: (Increase) Decrease in: Accounts Receivable (3,247,690) (4,773,738) Other Assets 50,283 29,767 Prepaid Expenses and Other Current Assets 284,107 210,701 Increase (Decrease) in: Accounts Payable and Accrued Liabilities 597,363 (229,255) ----------- ------------ NET CASH - OPERATING ACTIVITIES $ 980,209 $(1,218,190) ------------------------------- INVESTING ACTIVITIES: Acquisition of Equipment and Leasehold Improvements $ (274,344) $ (173,494) Acquisition of Medilabs, Inc. $ -- $(5,500,000) ----------- ----------- NET CASH - INVESTING ACTIVITIES $ (274,344) $(5,673,494) ------------------------------- FINANCING ACTIVITIES: Proceeds from Exercise of Options $ -- $ 25,314 Payments of Long-Term Debt (1,142,604) (281,961) Long-Term Acquisition Debt -- 5,500,000 Payments of Capital Lease Obligations (17,433) (45,369) Payments of Subordinated Notes Payable -- (1,339) Increase in Revolving Line of Credit -- 2,571,211 ----------- ----------- NET CASH - FINANCING ACTIVITIES $(1,160,037) $ 7,767,856 ------------------------------- ----------- ----------- NET INCREASE (DECREASE) IN CASH $ (454,172) $ 876,172 ------------------------------- CASH AT BEGINNING OF PERIODS 2,784,147 2,161,825 ---------------------------- ----------- ----------- CASH AT END OF PERIODS $ 2,329,975 $ 3,037,997 ---------------------- =========== =========== SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid during the period for: Interest $ 781,086 $ 434,116 Income Taxes $ 15,682 $ 192,150 The Accompanying Notes are an Integral Part of These Financial Statements. 4 SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: From March to July 1997, the Company incurred four capital leases obligations totaling $252,279 in connection with the acquisition of various medical equipment. In fiscal 1997, the Company issued debt in the amount of $108,000 in connection with the acquisition of a customer list related to a 1994 agreement. In May 1997, the Company issued 815,000 shares of common stock and warrants to purchase 58,534 shares of the Company's common stock at a price of $.71875 in connection with employment and consulting agreements and a two year extension on a loan agreement. Included in the 815,000 shares issued were 740,000 shares to three officers of the Company. The shares are forfeitable in part in various amounts if the employee's employment is terminated "for cause" or at his option "without good reason" as therein defined prior to May 1, 2000. On December 30, 1996, the Company commenced a lawsuit against SmithKline Beecham Clinical Laboratories ["SBCL"] alleging that SBCL materially and repeatedly breached its obligations and its representations and warranties made in the Asset Agreement and the Non-Competition Agreement pursuant to which the Company purchased certain assets from SBCL and claims unspecified amounts of compensatory and punitive damages and related costs. As a result of its allegations against SBCL, the Company did not make any payments with respect to the $600,000 note payable. In October 1998, the Company and SBCL exchanged general releases for this lawsuit and no executory obligations were imposed upon the Company by the settlement agreement. Therefore, the Company cancelled the $600,000 note payable as well as the related goodwill of approximately $550,000. The settlement was subject to the consent of the Company's principal lending bank which consent was received in January 1999. In January 1999, the Company issued 10,000 shares to an employee for services rendered. The Accompanying Notes are an Integral Part of These Consolidated Financial Statements. 5 BIO-REFERENCE LABORATORIES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) [1] In the opinion of management, the accompanying unaudited condensed financial statements reflect all adjustments [consisting only of normal adjustments and recurring accruals] which are necessary to present a fair statement of the results for the interim periods presented. [2] The results of operations for the six month period ended April 30, 1999 are not necessarily indicative of the results to be expected for the entire year. [3] The financial statements and notes thereto should be read in conjunction with the financial statements and notes for the year ended October 31, 1998 as filed with the Securities and Exchange Commission in the Company's Annual Report on Form 10-K. [4] Revenues are recognized at the time the services are performed. Revenues on the statement of operations is net of the following amounts for allowances and discounts. Three Months Ended Six Months Ended April 30 April 30 1999 1998 1999 1998 ---- ---- ---- ---- $18,314,710 $12,406,505 $34,022,933 $22,607,404 A number of proposals for legislation or regulation are under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken. [5] An allowance for contractual credits and uncollectible accounts is determined based upon a review of the reimbursement policies and subsequent collections for the different types of receivables. This allowance, which is net against accounts receivable was $13,239,835 at April 30, 1999 and $14,212,816 at April 30, 1998. [6] Inventory, consisting primarily of purchased clinical supplies, is valued at the lower of cost (first-in, first-out) or market. [7] Property and equipment are carried at cost. Depreciation is computed by the straight-line method over the estimated useful lives of the respective assets which range from 2 to 8 years. Leasehold improvements are amortized over the life of the lease, which is approximately five years. On sale or retirement, the asset cost and related accumulated depreciation or amortization are removed from the accounts, and any related gain or loss is reflected in income. Repairs and maintenance are charged to expense when incurred. [8] The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. [9] Cash equivalents are comprised of certain highly liquid investments with a maturity of three months or less when purchased. 6 [10] The Company adopted SFAS 128, "Earnings per share" in these financial statements. Basic income per share is based on the weighted average number of shares of common stock outstanding during each period. Diluted income per share includes the effects of assumed exercise of outstanding options and warrants and the issuance of potential common shares, if dilutive. At April 30, 1999 and April 30, 1998 the potential issuance of common shares upon exercise of outstanding options and warrants was anti-dilutive. The effects of deferred compensation is included by applying the treasury stock method. [11] The Company adopted Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation," on November 1, 1996 for financial note disclosure purposes and continues to apply the intrinsic value method of Accounting Principles Board ["APB"] Opinion No. 25, "Accounting for Stock Issued to Employees," for financial reporting purposes. [12] Certain long-term assets of the Company including goodwill are reviewed at least annually as to whether their carrying value has become impaired, pursuant to guidance established in Statement of Financial Accounting Standards ["SFAS"] No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of." Management considers assets to be impaired if the carrying value exceeds the future projected cash flows from related operations undiscounted and without interest charges. If impairment is deemed to exist, the assets will be written down to fair value or projected discounted cash flows from related operations. Management also re-evaluates the periods of amortization to determine whether subsequent events and circumstances warrant revised estimates of useful lives. Management reviewed the carrying value of certain long-term assets of the Company during the quarter ended April 30, 1999 and determined that impairment of certain of the long-term assets did exist. The Company decided to take a charge against earnings of approximately $2,924,000 on these assets. This decision was based upon an analysis of the profitability of each customer acquired in the initial transaction and whether the customer was still active. [13] The Company, at times, issues shares of common stock in payment for services rendered to the Company. The estimated fair value of the shares issued approximates the value of the services provided. [14] Deferred income tax assets and liabilities are computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. [15] At October 31, 1998, the Company had a deferred tax asset of approximately $2,000,000 and a valuation allowance of approximately $1,656,000 related to the asset, a decrease of $ 286,000 since October 31, 1997. The deferred tax asset primarily relates to net operating loss carry forwards. [16] At April 30, 1999, the Company had $3,680,000 of restricted cash which represents collateral for two demand notes issued pursuant to bank loans. [17] At April 30, 1999, the Company had approximately $5,649,000 in cash in excess of the federally insured limits, however $ 3,680,000 of this amount represents collateral for demand loans with the same banks. [18] In April 1998, the Company amended its revolving loan agreement with PNC Bank. The maximum amount of the credit line available to the Company is the lesser of (i) $14,000,000 or (ii) 50% of the Company's qualified accounts receivable [as defined in the agreement] plus 100% of the face amount of the certificates of deposit pledged as collateral for this loan minus the amount of any portion of the 7 outstanding principal balance of the term loan which is deemed to be collateralized by the certificate of deposit. Interest on advances which are collateralized by certificates of deposit will be at 2% above the certificate of deposit interest rate. Interest on other advances will be at prime plus 1.25%. The credit line is collateralized by substantially all of the Company's assets [including $3,680,000 in certificates of deposit with PNC] and the assignment of a $4,000,000 life insurance policy on the president of the Company. The line of credit is available through March 2001and may be extended for annual periods by mutual consents, thereafter. The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and net worth, various financial ratios and insurance coverage. As of October 31, 1998 and 1997, the Company was in compliance with the covenant provisions of this agreement. As of April 30, 1999, $13,717,752 was outstanding pursuant to this facility. [19] In the normal course of its business, the Company is exposed to a number of asserted and unasserted potential claims. In the opinion of management, the resolution of these matters will not have a material adverse affect on the Company's financial position or results of operations. The Company is being represented by counsel in connection with various reviews being conducted by the Company's Medicare carrier. One review involved overpayments that occur in the normal course of business. The Company believes the overpayment will be approximately $150,000, of which approximately $75,000 has already been remitted to Medicare. Counsel representing the Company in this matter has advised that he cannot offer any opinion or projection at this time as to whether the anticipated liability will be resolved at $150,000 or whether it will be increased. Counsel has advised that based upon his review of documents, many of the claims that Medicare thought were duplicate payments were not in fact duplicates, but rather were properly billed. Counsel also advised that in view of the complexity of the issue, he believes the final overpayment will be an amount negotiated between the Company and Medicare. [20] On September 30, 1997, the Company entered into an agreement to sell certain customer lists, its "GenCare" trade name and rights under two GenCare contracts to another laboratory for $4,600,000 in cash and $1,400,000 payable in four equal installments every six months beginning April 1, 1998, provided however that certain target revenues are reached. If target revenues are not reached amounts payable under the contract will be decreased up to a maximum of $700,000. The Company and certain of its officers entered into a non-competition agreement with the purchaser as part of this agreement. The Company recorded a non-recurring gain of $2,025,689 related to this sale. The $700,000 in contingent receivables were not included in the calculation of gain on this sale as of October 31, 1997. In August 1998, the Company was advised by the purchaser that the target revenues had been achieved. 8 Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS RESULTS OF OPERATIONS COMPARISON OF SECOND QUARTER 1999 VS SECOND QUARTER 1998 NET REVENUES: Net revenues for the three month period ended April 30, 1999 were $13,419,503 as compared to $10,808,505 for the three month period ended April 30, 1998; this represents a 24% increase in net revenues. On April 9, 1998, the Company acquired Medilabs, Inc. ("MLI"). MLI had net revenues of approximately $3,516,800 or 26% of the Company's net revenues for the most recent quarter. The number of patients serviced during the three month period ended April 30, 1999 was 312,569 which was 47% greater when compared to the prior fiscal year's three month period. MLI accounted for 36% of the patient count for the three month period ended April 30, 1999. Net revenue per patient (including MLI) for the three month period ended April 30, 1999 was $42.93 compared to net revenue per patient of $50.96 for the three month period ended April 30, 1998, a reduction of $8.03 or 16%. MLI's net revenue per patient was $31.45 for the three month period ended April 30, 1999. COST OF SALES: Cost of Services increased from $5,529,898 for the three month period ended April 30, 1998 to $7,946,027 for the three month period ended April 30, 1999, an increase of $2,416,129 or 44%. This increase is the result of the MLI acquisition. MLI's direct operating costs were approximately $2,444,500 for the three month period ended April 30, 1999. The continuing consolidation of laboratory operations has not been completed. No significant positive impact on the Company's cost structure is expected until later in fiscal year 1999. GROSS PROFITS: Gross profits on net revenues increased from $5,278,607 for the three month period ended April 30, 1998 to $5,473,476 for the three month period ended April 30, 1999; an increase of $194,869 or less than 4%, primarily attributable to the increase in net revenues. The decrease in gross profit margins from 49% to 41% is primarily attributable to the lower net revenues per patient, the increase in direct costs associated with MLI and the duplication of direct costs that had not been eliminated as of April 30, 1999 by an optimum consolidation of laboratory operations. Any continued decrease in net revenue per patient could adversely affect gross profits. GENERAL AND ADMINISTRATIVE EXPENSES: General and administrative expenses for the three month period ending April 30, 1999 were $8,729,277 as compared to $4,976,557 for the quarter ended April 30, 1998, an increase of $3,752,690 or 75%. This increase is caused primarily by a write-down of an impaired asset of $924,371 for the Company's end stage renal dialysis business acquired from Smith Kline Beecham and its associated increase in reserves on its accounts receivable of $2,000,000. Without the adjustment for the impaired asset, the increase in indirect expenses would have been $828,319 or 17%.MLI contributed approximately $800,000 of this increase. INTEREST EXPENSE: 9 Interest expense increased from $258,280 during the three month period ending April 30, 1998 to $375,903 during the three month period ended April 30, 1999 and is due to the Company's increase in asset based borrowing. This trend is expected to continue due to the MLI acquisition. INCOME (LOSS): The Company had net income of $123,998 for the three months ended April 30, 1998 as compared to a loss of $3,526,517 for the three months ended April 30, 1999 a decrease of $3,650,515. The primary reason for this loss is the write-down of the impaired asset and its associated additional reserve on the Company's end stage renal dialysis business acquired from Smith Kline Beecham. In addition, gross profit margins decreased from 49% for the three month period ended April 30, 1998 to 41% for the three month period ended April 30, 1999. SIX MONTHS 1999 COMPARED TO SIX MONTHS 1998 NET REVENUES: Net Revenues for the six month period ended April 30, 1998 were $19,744,928 as compared to $26,059,986 for the current six month period ended April 30, 1999; this represents a 32% increase in net revenues. MLI had net revenues of approximately $6,802,400 or 26% of the Company's net revenues for the six month period ended April 30, 1999. The number of patients serviced during the six month period ended April 30, 1999 was 592,313 which was 54% greater when compared to the prior fiscal year's six month period. MLI accounted for 36% of the patient count for the six month period ended April 30, 1999. Net revenue per patient (including MLI) for the six month period ended April 30, 1999 was $44.00, compared to net revenue per patient for the six month period ended April 30, 1998 of $51.43, a reduction of $7.43 or 14%. MLI's net revenue per patient was $32.25 for the six month period ended April 30, 1999. In April 1998, the Company acquired MLI and was awarded, as of November, 1998, a contract to provide laboratory testing by the New York State Department of Corrections for inmates in its facilities. The Company is seeking to expand its marketing efforts to other correctional institutions, nursing homes, pre-employment drug testing for employers and hospital reference testing and has hired new marketing representatives to specialize in this initiative. Management believes that the reimbursement rates for these tests will be somewhat lower than its current reimbursement rates. COST OF SALES: Cost of Services increased from $10,029,008 for the six month period ended April 30, 1998 to $15,152,499 for the six month period ended April 30, 1999. This represents a 51% increase in direct operating costs. This increase is the result of the MLI acquisition. MLI's direct operating costs were approximately $4,648,000 for the six month period ended April 30, 1999. The continuing consolidation of laboratory operations has not been completed. No significant positive impact on the Company's cost structure is expected until later in fiscal year 1999. GROSS PROFITS: Gross profits on net revenues increased from $9,715,920 for the six month period ended April 30, 1998 to $10,907,487 for the six month period ended April 30, 1998; an increase of $1,191,567 (12%), primarily attributable to the increase in net revenues. The decrease in gross profit margins, 49% to 42%, is primarily attributable to the lower net revenues per patient, the increase in direct costs associated with 10 MLI and the duplication of direct costs that had not been eliminated as of April 30, 1999 by an optimum consolidation of laboratory operations. Any continued decrease in net revenue per patient could adversely affect gross profits. 11 GENERAL AND ADMINISTRATIVE EXPENSES: General and administrative expenses for the six month period ending April 30, 1999 were $13,947,072 as compared to $9,238,469 for the six month period ended April 30, 1998, an increase of $4,708,603 or 51%. This increase is caused primarily by a write-down of an impaired asset of $924,371 for the Company's end stage renal dialysis business acquired from Smith Kline Beecham and its associated increase in reserves on its accounts receivable of $2,000,000. Without the adjustment for the impaired asset, the increase in indirect expenses would have been $1,784,232 or 19%. MLI contributed approximately $1,575,000 of this increase. INTEREST EXPENSE: Interest expense increased from $463,597 during the six month period ending April 30, 1998 as compared to $778,997 during the six month period ending April 30, 1999 and is the result of the Company's increase in asset based borrowing. This trend is expected to continue due to the MLI acquisition. INCOME: The Company had net income of $161,990 for the six months ended April 30, 1998 as compared to a loss of $3,634,257 for the six months ended April 30, 1999 a decrease of $3,796,247. The primary reason for this loss is the write-down of an impaired asset and its associated additional reserve on the Company's end stage renal dialysis business acquired from Smith Kline Beecham. In addition, gross profit margins decreased from 49% for the six month period ended April 30, 1998 to 42% for the six month period ended April 30, 1999. LIQUIDITY AND CAPITAL RESOURCES: Working capital as of April 30, 1999 was approximately $5,375,000 as compared to approximately $8,400,000 at October 31, 1998. The Company decreased its cash position by approximately $500,000 during the current six month period. The Company repaid approximately $1,200,000 in existing debt. The Company had current liabilities of approximately $21,400,000 at April 30, 1999. The three largest items in this category are notes payable of approximately $12,000,000, accounts payable of approximately $4,900,000 and current portion of long-term debt of approximately $2,000,000. Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base. The Company does have significant receivable balances with government payors and various insurance carriers. Generally, the Company does not require collateral or other security to support customer receivables, however, the Company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable. The Company establishes an allowance for uncollectible accounts. A number of proposals for legislation are under discussion which could substantially reduce Medicare and Medicaid reimbursements to clinical laboratories. Depending upon the nature of regulatory action, and the content of legislation, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken. In April 1998, the Company amended its revolving loan agreement with PNC Bank. The maximum amount of the credit line available to the Company is the lesser of (1) $14,000,000 or (ii) 50% of the Company's qualified accounts receivable [as defined in the agreement] plus 100% of the face amount of 12 the certificates of deposit pledged as collateral for this loan minus the amount of any portion of the outstanding principal balance of the term loan which is deemed to be collateralized by the certificates of deposit. Interest on advances which are collateralized by certificates of deposit will be at 2% above the certificate of deposit interest rate. Interest on other advances will be at prime plus 1.25%. The credit line is collateralized by substantially all of the Company's assets [including $3,680,000 in certificates of deposit with PNC] and the assignment of a $4,000,000 life insurance policy on the president of the Company. The line of credit is available through March 2001 and may be extended for annual periods by mutual consent thereafter. The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and net worth, various financial ratios and insurance coverage. As of October 31, 1998 and 1997, the Company was in compliance with the covenant provisions of this agreement. As of April 30, 1999, the Company was utilizing $12,000,000 of this credit facility. The Company's cash balances at April 30, 1999 were approximately $2,330,000 as compared to approximately $2,784,000 at October 31, 1997. The Company believes that its cash position, the anticipated cash generated from operations, the expanded use of its credit line with PNC Bank, the utilization of certificates of deposits maturing during the third quarter of fiscal year 1999 and the interest due thereupon, will meet its future cash needs. Project 2000 The Company is in the process of identifying those systems that require changes to accommodate the year 2000. It has identified four areas of concern. They are the laboratory's operations and billing systems, the general accounting systems and the two systems outside of its control; one being the payor systems and the other being the vendor systems. Management estimates that the laboratory operations and billing systems will require changes that translate into approximately $50,000 in costs. The general accounting systems (which are supplied by an outside vendor) will cost the Company approximately $25,000 and were upgraded in February, 1999. The payor systems are being converted per instructions on the part of each payor (i.e. Medicare, Medicaid, insurance companies, etc.). For example, electronic claims filing for Medicare has been completed, while the Company has been told not to make any changes for New Jersey Medicaid until it is notified to do so. The Company had not received notification from New Jersey Medicaid as of January 26, 1999. Once the general accounting systems are converted to accommodate the year 2000, the Company is confident that it will accept the input of all vendor invoices. During May 1998, the General Accounting Office ("GAO") warned the House Ways and Means Oversight Panel, "If progress is not made faster to assure correct and prompt claims processing and payment when the year 2000 dawns, the potential impact on the revenue and cash flow of pathologists, radiologists, laboratories and other providers could be catastrophic, including improper denials and payments that are late or incorrect." In the "National Intelligence Report" issue of January 12, 1999 it was disclosed that the Health Care Financing Administration ("HCFA") has posted some Y2K-related websites, a table of Medicare claims processing changes required for billing compliance, and more. HCFA stresses that every piece of hardware or software that is dependent on a microchip or date entry may be affected. In terms of HCFA's Y2K readiness, the agency stated that work has been completed to renovate, test, and validate all internal mission-critical systems and progress has been made with its carriers and intermediaries. The final systems to be considered by the Company are those of its vendors. Once the general accounting systems are converted to accommodate the year 2000, the Company is confident that it will accept the input of all vendor invoices. Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-K contains historical information as well as forward-looking statements. Statements looking forward in time are included in this Annual Report pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to be materially different from any future performance suggested herein. Impact of Inflation 13 To date, inflation has not had a material effect on the Company's operations. New Authoritative Pronouncements In February 1998, the FASB issued SFAS No. 132, "Employers Disclosure about Pension and Other Postretirement Benefits, " which is effective for fiscal years after December 15,1997. The modified disclosure requirements are not expected to have a material impact on the Company's results of operations, financial position or cash flows. In June 1998, the FASB issued SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities," which is effective for fiscal years beginning after June 15,1999. The Company will evaluate the new standard to determine any required new disclosures or accounting. PART II - OTHER INFORMATION Item 6 EXHIBITS AND REPORTS ON FORM 8-K The Company has filed no reports on Form 8-K during the quarter ended April 30, 1999. 14 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIO-REFERENCE LABORATORIES, INC. (Registrant) /S/ Marc D. Grodman Marc D. Grodman, M.D. President /S/ Sam Singer Sam Singer Chief Financial and Accounting Officer Date: June , 1999 15 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIO-REFERENCE LABORATORIES, INC. (Registrant) Marc D. Grodman, M.D. President Sam Singer Chief Financial and Accounting Officer Date: June 18, 1999 14